Evaluating Treatment Effect Based on Duration of Response

This study evaluates the duration of response for crizotinib vs chemotherapy for patients with ALK-positive lung cancer using data from the PROFILE-1014 randomized clinical trial.

https://ift.tt/2HO8WnS